OverviewSuggest Edit

Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
TypePrivate
Founded2012
HQPlan-les-Ouates, CH
Websiteobseva.com

Latest Updates

Employees (est.) (Sept 2021)52(-1%)
Cybersecurity ratingBMore

Key People/Management at ObsEva

Ernest Loumaye

Ernest Loumaye

Co-Founder, CEO & Director
David Renas

David Renas

Chief Financial Officer
Jean-Pierre Gotteland

Jean-Pierre Gotteland

Chief Scientific Officer and Head of R&D
Elizabeth Garner

Elizabeth Garner

Chief Medical Officer
Ed Mathers

Ed Mathers

Director
Fabien de Ladonchamps

Fabien de Ladonchamps

Chief Administrative Officer
Show more

ObsEva Office Locations

ObsEva has offices in Plan-les-Ouates, Boston and Sacramento
Plan-les-Ouates, CH (HQ)
Chemin des Aulx 12
Boston, MA, US
675 Atlantic Ave 2nd floor
Sacramento, CA, US
400 R St
Show all (3)

ObsEva Financials and Metrics

Summary Metrics

Founding Date

2012

ObsEva total Funding

$92.9 m

ObsEva latest funding size

$60 m

Time since last funding

6 years ago

ObsEva investors

ObsEva's latest funding round in November 2015 was reported to be $60 m. In total, ObsEva has raised $92.9 m
Show all financial metrics

ObsEva Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

ObsEva Online and Social Media Presence

Embed Graph

ObsEva News and Updates

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one invest…

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-

ObsEva to Present at Upcoming Investor Conferences

GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Confe…

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia–
Show more

ObsEva Blogs

Q1 Report 2021

The post Q1 Report 2021 appeared first on ObsEva.

ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 – May 2, 2021

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company... The post ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 – May 2, 2021 appeared first on ObsEva.

ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants

-Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3... The post ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants appeared first on ObsEva.

ObsEva Annual General Meeting 2021

Geneva, Switzerland and Boston, MA – April 22, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve... The post ObsEva Annual General Meeting 2021 appeared first on ObsEva.

Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials

G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020 The post Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embr…

PharmaBoardroom interview with Brian O’Callaghan – CEO, ObsEva

The post PharmaBoardroom interview with Brian O’Callaghan – CEO, ObsEva appeared first on ObsEva.
Show more

ObsEva Frequently Asked Questions

  • When was ObsEva founded?

    ObsEva was founded in 2012.

  • Who are ObsEva key executives?

    ObsEva's key executives are Ernest Loumaye, David Renas and Jean-Pierre Gotteland.

  • How many employees does ObsEva have?

    ObsEva has 52 employees.

  • Who are ObsEva competitors?

    Competitors of ObsEva include Skyepharma, Recro Gainesville and Amicus Therapeutics.

  • Where is ObsEva headquarters?

    ObsEva headquarters is located at Chemin des Aulx 12, Plan-les-Ouates.

  • Where are ObsEva offices?

    ObsEva has offices in Plan-les-Ouates, Boston and Sacramento.

  • How many offices does ObsEva have?

    ObsEva has 3 offices.